// STATE LEGISLATION TRACKER

Georgia HB 332: Controlled substances; Schedules I, IV, and V; provide certain provisions

⚖️ NEUTRAL for peptide users 👤 NONE user impact 📜 Status: Signed

State: Georgia
Bill: HB 332
Filed: 2023-02-09
Read the bill: OpenStates →
Last reviewed: 2026-10-02

Plain-English Summary

Georgia HB 332 was an annual controlled-substances update that changed Georgia drug schedules and the list of dangerous drugs. Based on the title, summary, and status available, it does not appear to directly regulate compounded peptides, off-label peptide prescribing, telehealth, NP/naturopath scope, or FDA 503A/503B compounding.

Key Points

No direct peptide-compounding change is apparent from the available summary.
Peptide users should not treat this as a new peptide ban or access expansion.
Clinicians prescribing controlled drugs in Georgia should check the updated schedules.
No apparent change to telehealth peptide prescribing rules.
No apparent change to NP or naturopath peptide scope.

What to Watch For

Note The bill is relevant mainly if a treatment plan includes controlled substances, not typical compounded peptides.

Note Georgia clinicians should confirm whether any drug they prescribe was added to or removed from a schedule.

Note No available summary points to changes in FDA 503A or 503B compounding rules.

Where the Bill Stands

The bill completed legislative action in 2023 and appears on Georgia's signed legislation list, with an effective date reported in 2023.

· Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-11-04 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws